Highlights
- •The largest ambispective study from a developing country on natalizumab and multiple sclerosis.
- •Natalizumab was found to be highly effective in Indian patients with MS.
- •Patients with RRMS and SPMS improved in relapse rate while EDSS improvement was observed only in the RRMS cohort.
- •The risk-benefit ratio appears highly favorable with no reports of PML.
Abstract
Background
Natalizumab (NTZ) is increasingly being used in Indian multiple sclerosis (MS) patients.
There are no reports on its safety and efficacy, especially with respect to the occurrence
of progressive multifocal leukoencephalopathy (PML).
Objectives
To describe the patient characteristics, treatment outcomes, and adverse events, especially
the occurrence of PML in NTZ-treated patients.
Methods
A multicentre ambispective study was conducted across 18 centres, from Jan 2012 to
Dec 2021. Patients at and above the age of 18 years treated with NTZ were included.
Descriptive and comparative statistics were applied to analyze data.
Results
During the study period of 9 years, 116 patients were treated with NTZ. Mean age of
the cohort was 35.6 ± 9.7 years; 83/116 (71.6%) were females. Relapse rate for the
entire cohort in the year before NTZ was 3.1 ± 1.51 while one year after was 0.20±0.57
(p = 0.001; CI 2.45 -3.35). EDSS of the entire cohort in the year before NTZ was 4.5 ± 1.94
and one year after was 3.8 ± 2.7 (p = 0.013; CI 0.16–1.36). At last follow up (38.3 ± 22.78 months) there were no cases
of PML identified.
Conclusions
Natalizumab is highly effective and safe in Indian MS patients, with no cases of PML
identified at last follow up.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.Ann. Neurol. 2016; 79: 950-958
- Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.JAMA. 2019; 321 (Erratum in: JAMA. 2020 Apr 7;323(13):1318. PMID: 30644981; PMCID: PMC6439772): 175-187https://doi.org/10.1001/jama.2018.20588
- Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).J. Neurol. Neurosurg. Psychiatry. 2020; 91: 660-668
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.Lancet Neurol. 2010; 9: 438-446https://doi.org/10.1016/S1474-4422(10)70028-4
- α4-integrin receptor desaturation and disease activity return after natalizumab cessation.Neurol. Neuroimmunol. Neuroinflamm. 2017; 4 (PMID: 28856176; PMCID: PMC5572051): e388https://doi.org/10.1212/NXI.0000000000000388
- Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Patient Prefer. Adherence. 2017; 11 (PMID: 28670113; PMCID: PMC5481282): 1035-1048https://doi.org/10.2147/PPA.S134865
- Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Patient Prefer Adherence. 2017; 11 (PMID: 28670113; PMCID: PMC5481282): 1035-1048https://doi.org/10.2147/PPA.S134865
- Updated Incidence of Natalizumab Associated Progressive Multifocal Leukoencephalopathy (PML) and its relationship with natalizumab exposure overTime.in: Presented at: 2020 American Academy of Neurology (AAN) Annual Meeting, Toronto, Canada2020 (April 25th May 1st)
- MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.Lancet Neurol. 2020; 19: 307-316
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.Lancet Neurol. 2017; 16: 925-933https://doi.org/10.1016/S1474-4422(17)30282-X)
- Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers.Neurol. Ther. 2015; 4: 147-157
- Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country.Mult. Scler. Relat. Disord. 2020; 43 (Epub 2020 May 24. PMID: 32485634)102210https://doi.org/10.1016/j.msard.2020.102210
- A controlled trial of natalizumab for relapsing multiple sclerosis.N. Engl. J. Med. 2003; 348: 15-23
- Low-dose rituximab should be used for treating MS in resource-limited settings: yes.Mult. Scler. 2022; (Epub ahead of print. PMID: 35437089)13524585221089890https://doi.org/10.1177/13524585221089890
- AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N. Engl. J. Med. 2006; 354: 899-910
- Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.Ther. Adv. Neurol. Dis. 2019; 121756286419837809https://doi.org/10.1177/1756286419837809
- Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.Mult. Scler. Relat. Disord. 2014; 3 (DeLuca, Andrea [corrected to De Luca, Andrea]. PMID: 20298967.) (Epub 2014 Apr 13. PMID: 25877065)): 520-526https://doi.org/10.1016/j.msard.2014.04.003
- Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.Mult. Scler. Relat. Disord. 2014; 3 (Epub 2014 Apr 13. PMID: 25877065): 520-526https://doi.org/10.1016/j.msard.2014.04.003
Article info
Publication history
Published online: July 24, 2022
Accepted:
July 15,
2022
Received in revised form:
July 9,
2022
Received:
June 18,
2022
Identification
Copyright
© 2022 Elsevier B.V. All rights reserved.
